Pfizer’s vaccine is showing efficacy greater than 90%, and an emergency use authorization (EUA) was granted by the FDA on December 11. The FDA Briefing Document is available for review here.


Moderna’s vaccine is showing a 95% efficacy rate and the vaccine can safely be stored at -25 degrees Fahrenheit. (December 31, 2020) Their EUA application was approved on December 18. The FDA briefing document is available for review here.


    The UK authorized use of the AstraZeneca vaccine on December 30. 

    AstraZeneca announced that its vaccine is showing a 70% efficacy rate on average, with some groups seeing up to 90% efficacy; further study is expected. (November 23, 2020). 

    Johnson & Johnson Ad26.COV2.S COVID-19 Vaccine
    • Interim results from the phase 1-2a trial of the Johnson & Johnson vaccine were reported in the NEJM on January 13. This vaccine is a recombinant, replication-incompetent adenovirus 26 vector encoding a full length and stabilized SARS-CoV-2 spike protein. Results from two of three cohorts (18 to 55-year-olds and >/=65-year-olds) were reported. This trial examined the effects of single versus double dose, and low dose versus high dose.
    • Neutralizing antibody titers were detected in 90% or more of all participants on day 29 after the first vaccine dose and reached 100% by day 57 in 18 to 55-year-olds with a further increase in titers, regardless of vaccine dose or age group. Titers remained stable until at least day 71 in the 18 to 55-year olds, the latest time period in this study. A second dose provided an increase in titer by a factor of 2.6-2.9. Spike antibody titers were similar. On day 14, CD4+ T-cell responses were detected in 76 to 83% of the younger cohort, and 60 to 67% of the older cohort. CD8+ T cell responses followed a similar pattern.
    • Adverse reactions were similar to current vaccines, and occurred in 65 to 85% of recipients. The most common were fatigue, headache and myalgia.
    • Further analysis of one versus two dose schedules, along with efficacy, are being assessed now in a phase 3 trial.
    Additional Vaccine Information
    • The COVID-19 Task Force does not anticipate any contraindication for patients on allergen immunotherapy (AIT). However, it would be best to not get the two shots within 48 hours of each other to avoid confusion should a reaction occur.
    • British researchers have reported new data on the transmissibility of the new SARS-CoV-2 variant found in the UK and US. CDC officials have noted that the new variant appears unlikely to impact the effectiveness of the COVID-19 vaccine. The CDC is compiling information about the variants here.
    • This recent article from the Lancet explains why multiple vaccines may be needed across different populations. (November 14, 2020)
    • ACIP and ACOG recommend that vaccination should not be withheld from pregnant or lactating women, but they should be informed there are insufficient safety data available at this time. AAAAI research partner MotherToBaby has more information on the vaccine in pregnant and lactating women.